Synthetic Lethality-based Drugs and Targets Market Size is predicted to witness a 14.5% CAGR during the forecast period for 2025-2034.
Synthetic lethality refers to a genetic and cancer treatment notion in which the simultaneous dysfunction of two genes results in cell death, whereas the dysfunction of either gene alone does not have the same effect. This method is employed to create precise cancer treatments that take advantage of particular genetic weaknesses in cancerous cells. The market for synthetic lethality-based targets and medications has expanded rapidly due to growing interest in personalized medicine and cancer. Globally, the prevalence of cancer is increasing, which is driving up the need for novel treatments that target the genetic defects that cause cancer. By taking advantage of genetic connections, synthetic lethality presents a possible method of eliminating cancer cells while protecting healthy ones.
Moreover, by expediting the clearance process for innovative medications, favourable regulatory actions are stimulating investment in synthetic lethality research. Finally, but just as importantly, collaborations between pharmaceutical companies and academic institutions are driving market growth, accelerating the rate of drug development, and ultimately improving patient outcomes.
The synthetic lethality-based drugs and target market is segmented based on product type and end-user. The product type segment is further segmented into Monotherapy and Combination Therapy. By end-user, the market is segmented into medical research institutions, hospitals and clinics, and other areas.
The monotherapy category is expected to hold a major global market share in 2023. The development of monotherapy treatments—which selectively target cancer cells with faulty DNA repair mechanisms—has been fueled by advancements in precision medicine and genetic studies. The need for more potent and less toxic treatment options has been fueled by the rising incidence of cancer worldwide and the shortcomings of conventional medicines, establishing monotherapy as a viable substitute. The market has also expanded as a result of regulatory approvals and encouraging clinical trial outcomes for a number of synthetic lethality-based medications.
Growing investments in advanced research and development are driving a significant expansion in the Medical Research Institution category within the Synthetic Lethality-based Drugs and Targets Market. By using synthetic lethality to treat diseases that were previously incurable, these institutes are at the forefront of the search for new therapeutic targets and the development of cutting-edge treatment approaches. Additionally, stimulating innovation and quickening the conversion of scientific findings into clinical applications is the growth of cooperative efforts between pharmaceutical corporations and medical research institutions.
The North American synthetic lethality-based drugs and targets market is expected to report the maximum market revenue share in the near future, propelled by advancements in genomic science and the rising prevalence of cancer. Synthetic lethality has gained popularity by focusing on specific genetic flaws in cancer cells, which may lead to the development of highly customized medicines with fewer side effects than traditional treatments. Investments in biotechnology and increased funding for cancer research are driving the industry's growth. The application of personalized treatment plans and precision medicine is also contributing to the market's expansion. In addition, Asia Pacific is estimated to grow rapidly in the global synthetic lethality-based drugs and targets market. The rapid progress in biotechnology and cancer research in nations such as South Korea, Japan, and China is propelling the creation and use of synthetic lethality strategies. Furthermore, there is a growing need for novel and efficient treatment alternatives due to the rising incidence of cancer in the area.
|
Report Attribute |
Specifications |
|
Growth Rate CAGR |
CAGR of 14.5% from 2025 to 2034 |
|
Quantitative Units |
Representation of revenue in US$ Bn and CAGR from 2025 to 2034 |
|
Historic Year |
2021 to 2024 |
|
Forecast Year |
2025-2034 |
|
Report Coverage |
The forecast of revenue, the position of the company, the competitive market structure, growth prospects, and trends |
|
Segments Covered |
By Application, and Type |
|
Regional Scope |
North America; Europe; Asia Pacific; Latin America; Middle East & Africa |
|
Country Scope |
U.S.; Canada; U.K.; Germany; China; India; Japan; Brazil; Mexico; France; Italy; Spain; South East Asia; South Korea |
|
Competitive Landscape |
AbbVie, Chordia Therapeutics, GlaxoSmithKline, AstraZeneca, BeiGene, Clovis Oncology, Repare Therapeutics, SyntheX Labs, Pfizer, AtlasMedx, IDEAYA Biosciences, Mission Therapeutics, and Sierra Oncology. |
|
Customization Scope |
Free customization report with the procurement of the report and modifications to the regional and segment scope. Particular Geographic competitive landscape. |
|
Pricing And Available Payment Methods |
Explore pricing alternatives that are customized to your particular study requirements. |
Chapter 1. Methodology and Scope
1.1. Research Methodology
1.2. Research Scope & Assumptions
Chapter 2. Executive Summary
Chapter 3. Global Synthetic Lethality-based Drugs and Targets Market Snapshot
Chapter 4. Global Synthetic Lethality-based Drugs and Targets Market Variables, Trends & Scope
4.1. Market Segmentation & Scope
4.2. Drivers
4.3. Challenges
4.4. Trends
4.5. Investment and Funding Analysis
4.6. Industry Analysis – Porter’s Five Forces Analysis
4.7. Competitive Landscape & Market Share Analysis
4.8. Impact of Covid-19 Analysis
Chapter 5. Market Segmentation 1: by Type Estimates & Trend Analysis
5.1. by Type & Market Share, 2024 & 2034
5.2. Market Size (Value (US$ Mn) & Forecasts and Trend Analyses, 2021 to 2034 for the following by Type:
5.2.1. Monotherapy
5.2.2. Combination Therapy
Chapter 6. Market Segmentation 2: by Application Estimates & Trend Analysis
6.1. by Application & Market Share, 2024 & 2034
6.2. Market Size (Value (US$ Mn) & Forecasts and Trend Analyses, 2021 to 2034 for the following by Application:
6.2.1. Medical Research Institution
6.2.2. Hospital and Clinic
6.2.3. Other
Chapter 7. Synthetic Lethality-based Drugs and Targets Market Segmentation 3: Regional Estimates & Trend Analysis
7.1. North America
7.1.1. North America Synthetic Lethality-based Drugs and Targets Market Revenue (US$ Million) Estimates and Forecasts by Type, 2021-2034
7.1.2. North America Synthetic Lethality-based Drugs and Targets Market Revenue (US$ Million) Estimates and Forecasts by Application, 2021-2034
7.1.3. North America Synthetic Lethality-based Drugs and Targets Market Revenue (US$ Million) Estimates and Forecasts by country, 2021-2034
7.2. Europe
7.2.1. Europe Synthetic Lethality-based Drugs and Targets Market Revenue (US$ Million) Estimates and Forecasts by Type, 2021-2034
7.2.2. Europe Synthetic Lethality-based Drugs and Targets Market Revenue (US$ Million) Estimates and Forecasts by Application, 2021-2034
7.2.3. Europe Synthetic Lethality-based Drugs and Targets Market Revenue (US$ Million) Estimates and Forecasts by country, 2021-2034
7.3. Asia Pacific
7.3.1. Asia Pacific Synthetic Lethality-based Drugs and Targets Market Revenue (US$ Million) Estimates and Forecasts by Type, 2021-2034
7.3.2. Asia Pacific Synthetic Lethality-based Drugs and Targets Market Revenue (US$ Million) Estimates and Forecasts by Application, 2021-2034
7.3.3. Asia Pacific Synthetic Lethality-based Drugs and Targets Market Revenue (US$ Million) Estimates and Forecasts by country, 2021-2034
7.4. Latin America
7.4.1. Latin America Synthetic Lethality-based Drugs and Targets Market Revenue (US$ Million) Estimates and Forecasts by Type, 2021-2034
7.4.2. Latin America Synthetic Lethality-based Drugs and Targets Market Revenue (US$ Million) Estimates and Forecasts by Application, 2021-2034
7.4.3. Latin America Synthetic Lethality-based Drugs and Targets Market Revenue (US$ Million) Estimates and Forecasts by country, 2021-2034
7.5. Middle East & Africa
7.5.1. Middle East & Africa Synthetic Lethality-based Drugs and Targets Market Revenue (US$ Million) Estimates and Forecasts by Type, 2021-2034
7.5.2. Middle East & Africa Synthetic Lethality-based Drugs and Targets Market Revenue (US$ Million) Estimates and Forecasts by Application, 2021-2034
7.5.3. Middle East & Africa Synthetic Lethality-based Drugs and Targets Market Revenue (US$ Million) Estimates and Forecasts by country, 2021-2034
Chapter 8. Competitive Landscape
8.1. Major Mergers and Acquisitions/Strategic Alliances
8.2. Company Profiles
8.2.1. AbbVie
8.2.2. AstraZeneca
8.2.3. BeiGene
8.2.4. Clovis Oncology
8.2.5. GlaxoSmithKline
8.2.6. Pfizer
8.2.7. AtlasMedx
8.2.8. Chordia Therapeutics
8.2.9. IDEAYA Biosciences
8.2.10. Mission Therapeutics
8.2.11. Repare Therapeutics
8.2.12. Sierra Oncology
8.2.13. SyntheX Labs
8.2.14. Other Prominent Players
Synthetic Lethality-based Drugs and Targets Market By Product Type-
Synthetic Lethality-based Drugs and Targets Market By End-User-
Synthetic Lethality-based Drugs and Targets Market By Region-
North America-
Europe-
Asia-Pacific-
Latin America-
Middle East & Africa-
InsightAce Analytic follows a standard and comprehensive market research methodology focused on offering the most accurate and precise market insights. The methods followed for all our market research studies include three significant steps – primary research, secondary research, and data modeling and analysis - to derive the current market size and forecast it over the forecast period. In this study, these three steps were used iteratively to generate valid data points (minimum deviation), which were cross-validated through multiple approaches mentioned below in the data modeling section.
Through secondary research methods, information on the market under study, its peer, and the parent market was collected. This information was then entered into data models. The resulted data points and insights were then validated by primary participants.
Based on additional insights from these primary participants, more directional efforts were put into doing secondary research and optimize data models. This process was repeated till all data models used in the study produced similar results (with minimum deviation). This way, this iterative process was able to generate the most accurate market numbers and qualitative insights.
Secondary research
The secondary research sources that are typically mentioned to include, but are not limited to:
The paid sources for secondary research like Factiva, OneSource, Hoovers, and Statista
Primary Research:
Primary research involves telephonic interviews, e-mail interactions, as well as face-to-face interviews for each market, category, segment, and subsegment across geographies
The contributors who typically take part in such a course include, but are not limited to:
Data Modeling and Analysis:
In the iterative process (mentioned above), data models received inputs from primary as well as secondary sources. But analysts working on these models were the key. They used their extensive knowledge and experience about industry and topic to make changes and fine-tuning these models as per the product/service under study.
The standard data models used while studying this market were the top-down and bottom-up approaches and the company shares analysis model. However, other methods were also used along with these – which were specific to the industry and product/service under study.
